Generic entry timeline

Afinitor generics — when can they launch?

Afinitor (everolimus) · Novartis · 4 active US patents · 8 expired

Earliest patent expiry
2028-07-01
2 years remaining
Full patent estate to
2028-07-01
complete protection through 2028
FDA approval
2009
Novartis

Where Afinitor sits in the generic timeline

Imminent generic cliff: earliest active US patent for Afinitor expires in 2028 (~2 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Method of Use — 4 patents

FDA U-codes carved out by Afinitor patents

Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.

U-codeDescription
U-1681(no description)

Sample patent estate

Showing 4 of 4 active US patents. View full estate on the Afinitor drug page →

  • US9006224 Method of Use · expires 2028-07-01
    USPTO title: Neuroendocrine tumor treatment
  • US9006224 Method of Use · expires 2028-07-01
    USPTO title: Neuroendocrine tumor treatment
  • US9006224 Method of Use · expires 2028-07-01
    USPTO title: Neuroendocrine tumor treatment
  • US9006224 Method of Use · expires 2028-07-01
    USPTO title: Neuroendocrine tumor treatment

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on Afinitor — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →